Amprenavir

17 October 2007

Products Affected - Description

Amprenavir 50 mg capsules, GlaxoSmithKline
Amprenavir 150 mg capsules, GlaxoSmithKline
Amprenavir 15 mg/mL oral solution, GlaxoSmithKline

Reason for the Shortage

Amprenavir (Agenerase) 50 mg capsules and 15 mg/mL oral solution will be discontinued by the end of October, 2007¹; the 150 mg capsules were discontinued in 2004.² GlaxoSmithKline discontinued the product due to low use and also because amprenavir is no longer part of a preferred or alternative regimen for treating HIV.^1-3

Estimated Resupply Dates

Amprenavir is discontinued.¹

Implications for Patient Care

Treatment guidelines for HIV infection are available from the Department of Health and Human Services.³ Refer to these guidelines for specific recommendations. Fosamprenavir may be an alternative in some patients.^1,3

Related Shortages

• Ganciclovir Capsules
• Oseltamivir Phosphate
• Ribavirin Inhalation— Resolved

1. Dear Health Care Professional Letter. Discontinuation of Agenerase (amprenavir) oral solution and 50 mg capsules in the US. Available online at http://www.fda.gov/downloads/Drugs/DrugSafety/DrugShortages/ucm086035.pdf. Research Triangle Park, NJ: GlaxoSmithKline, August 2007.
2. Dear Health Care Professional Letter. Discontinuation of Agenerase (amprenavir) 150 mg capsules. Research Triangle Park, NC: GlaxoSmithKline, September 2004.
3. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services. October 10, 2006; 1-113. Available at http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf. Accessed October 16, 2007.

Updated

Created October 16, 2007, by M. Christina Beckwith, Pharm.D., and Erin R. Fox, Pharm.D., Drug Information Specialists. Copyright 2007, Drug Information Service, University of Utah, Salt Lake City, UT.

Back to Drug Shortage Product Bulletins